We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 12, 2021

Pyrotinib May Replace Lapatinib in Patients With HER2+ MBC

Cancer management and research

 

Additional Info

Cancer management and research
Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Cancer Manag Res 2021 Oct 01;13(xx)7165-7174, Y Sun, B Chen, J Li, L Peng, S Li, X Yu, L Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading